Drawing for CYPRIUM THERAPEUTICS

USPTO serial 87978937

CYPRIUM THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 5624302Status 702Registered
Filing date
Status date
Registration date
Dec 4, 2018
Examiner
JOHNSON, DONALD
Law office
FILE DESTROYED

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with CYPRIUM THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Devon E. White

Devon E. White WYRICK ROBBINS YATES & PONTON LLP4101 LAKE BOONE TRAILSUITE 300RALEIGH, NC 27607

Goods and services

ClassDescriptionStatusFirst use
042Development of pharmaceutical preparations and medicines; Development of pharmaceutical preparations and medicines for the treatment of Menkes disease and copper transport and metabolism diseases and disorders; Development of pharmaceutical preparations and medicines for the treatment of diseases and disorders where copper deficiency is present; Development of pharmaceutical preparations and medicines for the treatment of hematological and neurological disorders; [ Laboratory research services relating to pharmaceuticals; ] Medical research services; Pharmaceutical drug development services; Scientific research for medical purposes in the field of Menkes disease and copper transport and metabolism diseases and disorders; Scientific research for medical purposes in the field of diseases and disorders where copper deficiency is present; Scientific research for medical purposes in the field of hematological and neurological disorders [ ; Research in the field of pharmacogenetics; Conducting clinical trials for others in the field of pharmaceuticals ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 10, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jun 10, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jun 10, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 4, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Dec 4, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 4, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 31, 2018SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 30, 2018CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Oct 25, 2018SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 25, 2018DPCCDIVISIONAL PROCESSING COMPLETE—
Sep 26, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Sep 24, 2018IUAFUSE AMENDMENT FILED—
Sep 24, 2018DRRRDIVISIONAL REQUEST RECEIVED—
Sep 24, 2018ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Sep 24, 2018EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 10, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 24, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 4, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 3, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 3, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 3, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 2, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 2, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 2, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 14, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 13, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 13, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 13, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 13, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 13, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 8, 2017DOCKASSIGNED TO EXAMINER—
Mar 21, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 18, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance